Taraneh Bahremand
Tehran University of Medical Sciences, Iran
Title: Anticonvulsive Effects of Licofelone on PTZ Induced seizure in mice: A Role for NMDA receptors
Biography
Biography: Taraneh Bahremand
Abstract
Licofelone is a dual COX/5-LOX inhibitor which is approved as a potential treatment for osteoarthritis. Its anti-inflammatory and analgesic properties have been shown before. Besides, recent studies identified neuroprotective and anti-oxidative roles where oxidative stress underlies Central Nervous System disorders. The anti-seizure activity was demonstrated in several animal models of epilepsy. Seeking underlying mechanisms for central effects of this drug, researchers have suggested various neurotransmitters and neuro-modulators as likely targets of licofelone. The involvement of nitric oxide synthase (NOS) in anti-seizure mechanisms of licofelone is addressed recently. In the present behavioral investigation, we utilized pentylenetetrazole-induced clonic seizure model to seek consequences of licofelone administration. We investigated the role of NMDA in the anticonvulsant effect of Licofelone in the pentylenetetrazole (PTZ)-induced seizure in mice. Licofelone revealed anticonvulsant properties at the dose of 10 mg/kg (i.p) or higher in mice. MK801, a selective NMDA antagonist, significantly enhanced this anticonvulsant effects in combination with sub-effective dose (5mg/kg) of licofelone.
On the other hand, pre-treatment with selective NMDA agonist (D-Serine) reversed the anticonvulsant effects of licofelone. This data implies that antagonizing of NMDA receptors seems crucial for anticonvulsant properties of this COX/5- LOX inhibitor in seizure susceptibility. Our findings point to the involvement of NMDA as an essential role player in the central neuro-protective properties of licofelone.